Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa, a wholly owned subsidiary of Japan-based pharmaceutical and biotech company Kyowa Hakko Kirin, has licensed its patented Potelligent Technology platform to Oxford BioTherapeutics (OBT) for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
Subscribe to our email newsletter
Under the agreement, OBT will use Potelligent Technology for the manufacturing, development and commercializing chosen ADCC programs from its pipeline of preclinical antibodies for oncology, which it has built based upon novel targets identified using its OGAP proteomic database.
In return, OBT will pay to BioWa undisclosed license fees, development and commercialization milestones and royalties on sales of any products that it commercializes.
Research shows that Potelligent Technology enhances ADCC activity of an antibody in-vitro, and increases potency and efficacy of the antibody in-vivo.
OBT Oncology senior vice president Jon Terrett said the company’s cancer specific antibody portfolio has matured to an advanced stage where coupling to BioWa’s Potelligent Technology enhances already promising anticancer agents and further enables clinical development pipeline.